Introduction
Acute renal failure (ARF) is a serious complication of surgery and is associated with significant in-hospital and long-term morbidity and mortality, as well as prolonged hospital stay.
Fenoldopam mesylate, a benzazepine derivative, is the first selective dopamine-1-receptor agonist approved for clinical use (in hypertensive urgencies and emergencies). The selective dopaminergic action of fenoldopam appears to improve renal performance when renal blood flow is reduced such as in severe hypertension, (1, 2) hypertensive patients with pre-existing impaired renal function (3) and ventilation with positive end-expiratory pressure. (4) These effects are mediated by an increased renal blood flow to both cortex and medullary regions. Recent meta-analyses (5,6) and controlled studies (both case-matched (7) and randomized (8) ) suggested that fenoldopam could be effective in the prevention and treatment of ARF. Other Table 3 . Post-operative data of 64 patients who received either fenoldopam (n=32) or dopamine (n=32) to prevent perioperative acute renal failure.
Variables
Fenoldopam Dopamine p Acute renal failure (25% creatinine increase), n (%) 11 (34%) 14 (44%) 0.6
Acute renal failure (50% creatinine increase), n (%) 4 (12%) 7 (22%) 0.5
Acute renal failure (100% creatinine increase), n (%) 
Materials and methods
The study was carried out according to the principles of the Declaration of Helsinki. The ethical committee of San Raffaele Hospital (Milano, Italy) approved the study protocol. All patients were provided with written information and signed a written informed consent. Sixty-four consecutive eligible patients, 18 years of age or older, scheduled for urologic or vascular surgery at a tertiary university hospital were randomly assigned to receive either fenoldopam or dopamine.
We included patients at high risk of perioperative renal dysfunction such as patients undergoing nephrectomy plus removal of a controlateral tumor (in an urologic setting) or patients undergoing vascular surgery with aortic crossclamp who presented with a preoperative serum creatinine > 123 mol/l. Conversely, exclusion criteria included an emergency procedure, preoperative dialysis, glaucoma (to avoid the risk of increasing intra-ocular pressure associated with fenoldopam administration) and a previous adverse reaction to fenoldopam or its infusion components (metabisulfite or sulfitesprevious). Subjects were allocated according to randomization derived from a computer-generated list of random numbers, with no blocking, by an independent statistician. The details of the randomization were contained in a set of sealed opaque envelopes. These were available only shortly before anesthesia induction and were opened by independent research nurses that were not further involved in patients' management or follow up. Participants, care providers, and those assessing outcomes were all blinded to the assigned study drug.
Of the 85 eligible patients, 21 refused to sign the informed consent and did not take part in the study (figure 1 
Results
Patients receiving fenoldopam or dopamine showed a similar incidence of postoperative ARF: 11/32 (34%) in the fenoldopam group vs 14/32 (44%) in the dopamine group (p=0.6). No renal replacement therapy and no deaths were observed in this population. Baseline demographic and clinical characteristics are reported in table 1. All participants who underwent random allocation were analyzed according to group assignment. Table 2 shows the intraoperative data in the two study arms with no difference between groups in urinary output, heart rate, arterial pressure and use of vasoconstrictors. Table 3 shows postoperative data with no difference in the incidence of ARF between the two groups (patients receiving fenoldopam versus patients receiving dopamine), irrespective of definition used: 25% creatinine increase (34% versus 44% p=0.6); 50% creatinine increase (12% versus 22%p=0.5); 100% creatinine increase (3% versus 9% p=0.3).
In the overall population serum creatinine raised from a baseline level of 114±53 mol/l to a postoperative peak of 158+13 mol/l (p=0.008), while in the patients who developed ARF it showed a 85% increase, from 114+55 mol/l to 211+185 mol/l (p=0.01).
Discussion
The principal finding of this prospective, randomized, double-blinded trial is that a 0.05 mcg/kg/min dose of fenoldopam, lasting 12 hours, does not reduce the risk of perioperative acute renal failure when compared to dopamine. Our results are in accordance with only two previous reports in which fenoldopam was used at a low dosage (9) or for a short period of time. (10) All the other studies (7, 8, (13) (14) (15) (16) (17) (18) (19) (20) 
